374 related articles for article (PubMed ID: 35800156)
1. Oncolytic adenovirus with MUC16-BiTE shows enhanced antitumor immune response by reversing the tumor microenvironment in PDX model of ovarian cancer.
Wang Q; Ma X; Wu H; Zhao C; Chen J; Li R; Yan S; Li Y; Zhang Q; Song K; Yuan C; Kong B
Oncoimmunology; 2022; 11(1):2096362. PubMed ID: 35800156
[TBL] [Abstract][Full Text] [Related]
2. Oncolytic Adenoviral Delivery of an EGFR-Targeting T-cell Engager Improves Antitumor Efficacy.
Fajardo CA; Guedan S; Rojas LA; Moreno R; Arias-Badia M; de Sostoa J; June CH; Alemany R
Cancer Res; 2017 Apr; 77(8):2052-2063. PubMed ID: 28143835
[TBL] [Abstract][Full Text] [Related]
3. Targeting the tumor stroma with an oncolytic adenovirus secreting a fibroblast activation protein-targeted bispecific T-cell engager.
de Sostoa J; Fajardo CA; Moreno R; Ramos MD; Farrera-Sal M; Alemany R
J Immunother Cancer; 2019 Jan; 7(1):19. PubMed ID: 30683154
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-infiltrating lymphocyte tumor reactivity.
Santos JM; Heiniö C; Cervera-Carrascon V; Quixabeira DCA; Siurala M; Havunen R; Butzow R; Zafar S; de Gruijl T; Lassus H; Kanerva A; Hemminki A
J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31940588
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy.
Khalique H; Baugh R; Dyer A; Scott EM; Frost S; Larkin S; Lei-Rossmann J; Seymour LW
J Immunother Cancer; 2021 Mar; 9(4):. PubMed ID: 33820820
[TBL] [Abstract][Full Text] [Related]
6. Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus-Driven Production of a Bispecific T-cell Engager.
Wing A; Fajardo CA; Posey AD; Shaw C; Da T; Young RM; Alemany R; June CH; Guedan S
Cancer Immunol Res; 2018 May; 6(5):605-616. PubMed ID: 29588319
[TBL] [Abstract][Full Text] [Related]
7. Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses.
Watanabe K; Luo Y; Da T; Guedan S; Ruella M; Scholler J; Keith B; Young RM; Engels B; Sorsa S; Siurala M; Havunen R; Tähtinen S; Hemminki A; June CH
JCI Insight; 2018 Apr; 3(7):. PubMed ID: 29618658
[TBL] [Abstract][Full Text] [Related]
8. Potent antitumor effect of neurotensin receptor-targeted oncolytic adenovirus co-expressing decorin and Wnt antagonist in an orthotopic pancreatic tumor model.
Na Y; Choi JW; Kasala D; Hong J; Oh E; Li Y; Jung SJ; Kim SW; Yun CO
J Control Release; 2015 Dec; 220(Pt B):766-82. PubMed ID: 26471393
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic adenoviruses expressing checkpoint inhibitors for cancer therapy.
Xie D; Tian Y; Hu D; Wang Y; Yang Y; Zhou B; Zhang R; Ren Z; Liu M; Xu J; Dong C; Zhao B; Yang L
Signal Transduct Target Ther; 2023 Nov; 8(1):436. PubMed ID: 38016957
[TBL] [Abstract][Full Text] [Related]
10. Bi- and tri-valent T cell engagers deplete tumour-associated macrophages in cancer patient samples.
Scott EM; Jacobus EJ; Lyons B; Frost S; Freedman JD; Dyer A; Khalique H; Taverner WK; Carr A; Champion BR; Fisher KD; Seymour LW; Duffy MR
J Immunother Cancer; 2019 Nov; 7(1):320. PubMed ID: 31753017
[TBL] [Abstract][Full Text] [Related]
11. Combination immunotherapy using G-CSF and oncolytic virotherapy reduces tumor growth in osteosarcoma.
Morales-Molina A; Gambera S; Leo A; García-Castro J
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737338
[TBL] [Abstract][Full Text] [Related]
12. Targeted BiTE Expression by an Oncolytic Vector Augments Therapeutic Efficacy Against Solid Tumors.
Speck T; Heidbuechel JPW; Veinalde R; Jaeger D; von Kalle C; Ball CR; Ungerechts G; Engeland CE
Clin Cancer Res; 2018 May; 24(9):2128-2137. PubMed ID: 29437789
[No Abstract] [Full Text] [Related]
13. Oncolytic adenovirus expressing bispecific antibody targets T-cell cytotoxicity in cancer biopsies.
Freedman JD; Hagel J; Scott EM; Psallidas I; Gupta A; Spiers L; Miller P; Kanellakis N; Ashfield R; Fisher KD; Duffy MR; Seymour LW
EMBO Mol Med; 2017 Aug; 9(8):1067-1087. PubMed ID: 28634161
[TBL] [Abstract][Full Text] [Related]
14. Oncolytic adenovirus and gene therapy with EphA2-BiTE for the treatment of pediatric high-grade gliomas.
Arnone CM; Polito VA; Mastronuzzi A; Carai A; Diomedi FC; Antonucci L; Petrilli LL; Vinci M; Ferrari F; Salviato E; Scarsella M; De Stefanis C; Weber G; Quintarelli C; De Angelis B; Brenner MK; Gottschalk S; Hoyos V; Locatelli F; Caruana I; Del Bufalo F
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963009
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-7-loaded oncolytic adenovirus improves CAR-T cell therapy for glioblastoma.
Huang J; Zheng M; Zhang Z; Tang X; Chen Y; Peng A; Peng X; Tong A; Zhou L
Cancer Immunol Immunother; 2021 Sep; 70(9):2453-2465. PubMed ID: 33543339
[TBL] [Abstract][Full Text] [Related]
16. Engineered adenoviruses combine enhanced oncolysis with improved virus production by mesenchymal stromal carrier cells.
Hammer K; Kazcorowski A; Liu L; Behr M; Schemmer P; Herr I; Nettelbeck DM
Int J Cancer; 2015 Aug; 137(4):978-90. PubMed ID: 25604186
[TBL] [Abstract][Full Text] [Related]
17. CXCL11-armed oncolytic adenoviruses enhance CAR-T cell therapeutic efficacy and reprogram tumor microenvironment in glioblastoma.
Wang G; Zhang Z; Zhong K; Wang Z; Yang N; Tang X; Li H; Lu Q; Wu Z; Yuan B; Zheng M; Cheng P; Tong A; Zhou L
Mol Ther; 2023 Jan; 31(1):134-153. PubMed ID: 36056553
[TBL] [Abstract][Full Text] [Related]
18. Bioreducible polymer-mediated delivery of oncolytic adenovirus can attenuate antiviral immune response and concurrently enhance the induction of antitumor immune response to effectively prevent metastasis.
Kasala D; Lee SH; Hong J; Oh E; Yoon AR; Yun CO
Biomater Sci; 2022 Jul; 10(15):4293-4308. PubMed ID: 35766864
[TBL] [Abstract][Full Text] [Related]
19. Revolutionizing cancer treatment: the power of bi- and tri-specific T-cell engagers in oncolytic virotherapy.
Zarezadeh Mehrabadi A; Tat M; Ghorbani Alvanegh A; Roozbahani F; Esmaeili Gouvarchin Ghaleh H
Front Immunol; 2024; 15():1343378. PubMed ID: 38464532
[TBL] [Abstract][Full Text] [Related]
20. Enhanced antitumor efficacy of a novel oncolytic vaccinia virus encoding a fully monoclonal antibody against T-cell immunoglobulin and ITIM domain (TIGIT).
Zuo S; Wei M; He B; Chen A; Wang S; Kong L; Zhang Y; Meng G; Xu T; Wu J; Yang F; Zhang H; Wang S; Guo C; Wu J; Dong J; Wei J
EBioMedicine; 2021 Feb; 64():103240. PubMed ID: 33581644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
